RxDoctor Payments Data

Kelly Bennett

Family · Centennial, CONPI 1891184875

Payments from drug & device makers

$3,326in general payments, 2019–2025

Across 160 payments — averaging $20.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$997
  • Pfizer$438
  • AstraZeneca$291
  • Lilly USA, LLC$244
  • Otsuka America Pharmaceutical, Inc.$162
  • Johnson & Johnson$154
  • plus $1K from 24 others

What the payments were for

  • Food & beverage$3,24998%
  • Education$772%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,326 in reported general payments places this provider in the 90th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$1,951,772
Medicare patients
84
Services billed
82,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban17$22,607
JardianceEmpagliflozin15$17,232
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$15,596
Estradiol14$1,203
Levothyroxine Sodium48$714
Rosuvastatin Calcium37$603
Atorvastatin Calcium71$587
Bupropion XlBupropion Hcl13$522
Gabapentin19$387
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide22$332
Lisinopril40$315
Duloxetine Hcl12$305
Metformin Hcl ErMetformin Hcl22$267
Albuterol Sulfate HfaAlbuterol Sulfate11$260
Losartan Potassium17$189

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$438$22,60717 claims
Boehringer IngelheimJardiance$60$17,23215 claims
GSKTrelegy Ellipta$120$15,59612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,182 family providers in Colorado.

Other family in Centennial

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →